Cedax (ceftibuten)


Approval Status
Approved December 1995

Treatment for
chronic bronchitis, infection of the middle ear, pharyngitis/tonsillitis

Immune System , ENT (Ear, Nose and Throat) , Respiratory

Clinical studies have demonstrated that Cedax is active against a broad spectrum of bacteria that are common causes of upper and lower respiratory tract infections. These include most strains of Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, and Streptococcus pyogenes. Cedax is highly stable in the presence of beta-lactamases--enzymes produced by bacteria that can render some commonly used antibiotics, such as amoxicillin or penicillin, ineffective.

Clinical trials revealed a very low incidence of gastrointestinal side effects, including diarrhea.

Acute otitis media is the most commonly diagnosed infection among children today. By age three, 84 percent of all children will have experienced at least one episode of acute otitis media, and nearly 50 percent will have had three or more episodes.

Acute bacterial exacerbation of chronic bronchitis is a bacterial infection that frequently occurs in chronic bronchitis subjects. According to the American Lung Association, chronic bronchitis affects at least 13.8 million Americans.

Cedax (ceftibuten) Drug Information

The Cedax (ceftibuten) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top